BR112015011778A2 - métodos para administrar e avaliar drogas de expulsão de nitrogênio para o tratamento de encefalopatia hepática - Google Patents

métodos para administrar e avaliar drogas de expulsão de nitrogênio para o tratamento de encefalopatia hepática

Info

Publication number
BR112015011778A2
BR112015011778A2 BR112015011778A BR112015011778A BR112015011778A2 BR 112015011778 A2 BR112015011778 A2 BR 112015011778A2 BR 112015011778 A BR112015011778 A BR 112015011778A BR 112015011778 A BR112015011778 A BR 112015011778A BR 112015011778 A2 BR112015011778 A2 BR 112015011778A2
Authority
BR
Brazil
Prior art keywords
administering
methods
drugs
treatment
nitrogen
Prior art date
Application number
BR112015011778A
Other languages
English (en)
Inventor
Scharschmidt Bruce
Mokhtarani Masoud
Original Assignee
Hyperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyperion Therapeutics Inc filed Critical Hyperion Therapeutics Inc
Publication of BR112015011778A2 publication Critical patent/BR112015011778A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

resumo "métodos para administrar e avaliar drogas de expulsão de nitrogênio para o tratamento de encefalopatia hepática". a presente divulgação proporciona métodos para tratar encefalopatia hepática (he) e para otimizar e ajustar dosagem de droga de expulsão de nitrogênio para sujeitos com he compreendendo administrar uma droga de expulsão de nitrogênio em uma dosagem suficiente para manter a. nível de amônia no sangue em jejum num ou abaixo de um nível de limiar especificado que é de 1,5 vezes o limite superior do normal para amônia no sangue. a droga de expulsão de nitrogênio administrada no método é uma pró-droga de ácido fenilacético selecionada de hpn-100, pba, napba, benzoato de sódio ou qualquer combinação das mesmas (isto é, qualquer combinação de duas ou mais de hpn-100, pba, napba).
BR112015011778A 2012-11-21 2013-11-21 métodos para administrar e avaliar drogas de expulsão de nitrogênio para o tratamento de encefalopatia hepática BR112015011778A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261728967P 2012-11-21 2012-11-21
US201361759292P 2013-01-31 2013-01-31
PCT/US2013/071333 WO2014081977A1 (en) 2012-11-21 2013-11-21 Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy

Publications (1)

Publication Number Publication Date
BR112015011778A2 true BR112015011778A2 (pt) 2017-07-11

Family

ID=50728524

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015011778A BR112015011778A2 (pt) 2012-11-21 2013-11-21 métodos para administrar e avaliar drogas de expulsão de nitrogênio para o tratamento de encefalopatia hepática

Country Status (20)

Country Link
US (3) US9289406B2 (pt)
EP (2) EP3335735A1 (pt)
JP (1) JP2016506378A (pt)
KR (1) KR20150086510A (pt)
CN (1) CN104797272A (pt)
AU (1) AU2013347905B2 (pt)
BR (1) BR112015011778A2 (pt)
CA (1) CA2891657A1 (pt)
CY (1) CY1120163T1 (pt)
DK (1) DK2922576T3 (pt)
ES (1) ES2654774T3 (pt)
HK (2) HK1210699A1 (pt)
HR (1) HRP20180041T1 (pt)
HU (1) HUE036133T2 (pt)
LT (1) LT2922576T (pt)
PL (1) PL2922576T3 (pt)
PT (1) PT2922576T (pt)
RS (1) RS56757B1 (pt)
SI (1) SI2922576T1 (pt)
WO (1) WO2014081977A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2413924T3 (pt) 2009-04-03 2018-02-24
CA2997484C (en) 2009-06-08 2020-05-12 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
DK2760479T3 (en) 2011-09-30 2017-07-17 Horizon Therapeutics Llc Nitrogen-removing drug for use in a method of treating a nitrogen retention disorder
HUE032726T2 (en) 2012-04-20 2017-10-30 Horizon Therapeutics Llc HPN-100 for use in the treatment of nitrogen retention disorders
ES2654774T3 (es) * 2012-11-21 2018-02-15 Horizon Therapeutics, Llc Métodos para administrar y evaluar fármacos de recuperación de nitrógeno para el tratamiento de encefalopatía hepática
AU2015353703B2 (en) * 2014-11-24 2021-04-01 Ucl Business Plc Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
AU2016308641B2 (en) 2015-08-18 2022-02-03 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
EP3621947A4 (en) 2017-05-11 2021-03-10 Ocera Therapeutics, Inc. L-ORNITHINE PHENYLACETATE MANUFACTURING PROCESSES
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
EP0858441B1 (en) 1995-02-07 2001-05-09 Brusilow Enterprises, LLC Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
US6219567B1 (en) 1999-06-21 2001-04-17 Cardiox Corporation Monitoring of total ammoniacal concentration in blood
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US20050273359A1 (en) 2004-06-03 2005-12-08 Young David E System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure
CN1778963A (zh) * 2004-11-23 2006-05-31 苏州艾杰生物科技有限公司 血氨含量测定方法及血氨诊断试剂盒
PT2319581E (pt) 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
US20060135612A1 (en) 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
US20070004805A1 (en) 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
WO2007059031A2 (en) 2005-11-10 2007-05-24 Massachusetts Institute Of Technology Methods and compositions for raising levels and release of gamma aminobutyric acid
US8094521B2 (en) 2007-02-28 2012-01-10 Nightingale Products LLC Caregiver personal alert device
CN101959429B (zh) 2008-01-08 2014-09-10 阿克塞利亚制药公司 抗微生物肽系统的激动剂
US8642012B2 (en) 2008-04-29 2014-02-04 Hyperion Therapeutics, Inc. Methods of treatment using ammonia-scavenging drugs
US20120022157A1 (en) 2008-08-29 2012-01-26 Ucyclyd Pharma, Inc Dosing and monitoring patients on nitrogen-scavenging drugs
SI3133396T1 (sl) * 2008-08-29 2018-12-31 Horizon Therapeutics, Llc Postopki zdravljenja z uporabo zdravil, ki odstranjujejo amonijak
EP2456304B1 (en) * 2009-07-24 2015-08-19 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
JP6049619B2 (ja) 2010-08-31 2016-12-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ナノヒドロキシアパタイトを含む多孔質多糖足場、及び骨形成のための使用
DK2760479T3 (en) * 2011-09-30 2017-07-17 Horizon Therapeutics Llc Nitrogen-removing drug for use in a method of treating a nitrogen retention disorder
HUE032726T2 (en) * 2012-04-20 2017-10-30 Horizon Therapeutics Llc HPN-100 for use in the treatment of nitrogen retention disorders
ES2654774T3 (es) * 2012-11-21 2018-02-15 Horizon Therapeutics, Llc Métodos para administrar y evaluar fármacos de recuperación de nitrógeno para el tratamiento de encefalopatía hepática
EP3019074B1 (en) 2013-09-30 2018-08-29 Horizon Therapeutics, LLC Diagnosing, grading, monitoring, and treating hepatic encephalopathy
EP2986325B1 (en) 2013-10-14 2019-06-26 Immedica Pharma AB Methods of treating urea cycle disorders

Also Published As

Publication number Publication date
KR20150086510A (ko) 2015-07-28
SI2922576T1 (en) 2018-04-30
JP2016506378A (ja) 2016-03-03
AU2013347905A1 (en) 2015-04-30
ES2654774T3 (es) 2018-02-15
HK1210699A1 (en) 2016-05-06
US20140142186A1 (en) 2014-05-22
HUE036133T2 (hu) 2018-06-28
US9289406B2 (en) 2016-03-22
HK1213778A1 (zh) 2016-07-15
EP2922576B1 (en) 2017-11-08
AU2013347905B2 (en) 2018-10-04
CY1120163T1 (el) 2018-12-12
EP3335735A1 (en) 2018-06-20
DK2922576T3 (en) 2018-01-15
EP2922576A1 (en) 2015-09-30
CA2891657A1 (en) 2014-05-30
WO2014081977A1 (en) 2014-05-30
PL2922576T3 (pl) 2018-08-31
HRP20180041T1 (hr) 2018-06-01
PT2922576T (pt) 2018-01-24
LT2922576T (lt) 2018-02-12
US20160223520A1 (en) 2016-08-04
EP2922576A4 (en) 2016-05-04
RS56757B1 (sr) 2018-04-30
US20180017546A1 (en) 2018-01-18
CN104797272A (zh) 2015-07-22

Similar Documents

Publication Publication Date Title
BR112015011778A2 (pt) métodos para administrar e avaliar drogas de expulsão de nitrogênio para o tratamento de encefalopatia hepática
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
BRPI1011220A2 (pt) composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada.
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
CU20110100A7 (es) Tratamiento de pirfenidona para pacientes con función hepática atípica
BR112017006957A2 (pt) formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína
BR112015022465A2 (pt) método para tratamento não-tóxico para síndrome de abstinência de drogas
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
ECSP14012676A (es) Compuestos de carbamato y preparación y uso de los mismos
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112014029954A2 (pt) tratamento de tumores sólidos usando coenzima q10
CR20110243A (es) Tratamiento de pirfenidona para pacientes con función hepática.
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
AR104771A1 (es) Inhalador de polvo seco
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
MX2015016418A (es) Dihidroetorfina para proporcionar el alivio del dolor y la anestesia.
UY31790A (es) Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
FI3352735T3 (fi) Pitkitetysti vapauttavia olantsapiiniformulaatioita
ES2422563A1 (es) Composición farmacéutica inyectable de ibuprofeno y arginina, su procedimiento de preparación, forma de dosificación unitaria y utilización de la misma

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B06I Technical and formal requirements: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B25D Requested change of name of applicant approved

Owner name: HORIZON THERAPEUTICS, INC. (US)

B25D Requested change of name of applicant approved

Owner name: HORIZON THERAPEUTICS, LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A ANUIDADE.

B07E Notice of approval relating to section 229 industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2541 DE 17-09-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.